Autopsy report · NCT05039515

A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

“Following the planned FALKON Part A primary analysis, the study did not meet its primary endpoint of reducing heterotopic ossification (HO) volume compared with placebo and met predefined futility criteria.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 4 years 4 months before it stopped.
• 113 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Clementia Pharmaceuticals Inc.

Sponsor type

Industry

Conditions

Fibrodysplasia Ossificans Progressiva

Interventions

IPN60130; IPN60130; Placebo

Participants

113

Sites

25

Countries

Argentina, Australia, Belgium, Canada, China, France, Italy, Japan, Mexico, Portugal, South Korea, Spain and more

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.